EP3938478A1 - Utilisation d'huiles comprenant des additifs anti-usure non neurotoxiques - Google Patents
Utilisation d'huiles comprenant des additifs anti-usure non neurotoxiquesInfo
- Publication number
- EP3938478A1 EP3938478A1 EP21725231.1A EP21725231A EP3938478A1 EP 3938478 A1 EP3938478 A1 EP 3938478A1 EP 21725231 A EP21725231 A EP 21725231A EP 3938478 A1 EP3938478 A1 EP 3938478A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- diphenylphosphate
- bis
- oil
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007866 anti-wear additive Substances 0.000 title claims abstract description 39
- 239000003921 oil Substances 0.000 title claims description 96
- 231100000501 nonneurotoxic Toxicity 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- 206010029350 Neurotoxicity Diseases 0.000 claims abstract description 52
- 206010044221 Toxic encephalopathy Diseases 0.000 claims abstract description 52
- 231100000228 neurotoxicity Toxicity 0.000 claims abstract description 52
- 230000007135 neurotoxicity Effects 0.000 claims abstract description 52
- 231100000669 Aerotoxic syndrome Toxicity 0.000 claims abstract description 17
- 238000011321 prophylaxis Methods 0.000 claims abstract description 11
- 239000000779 smoke Substances 0.000 claims abstract description 10
- ASMQGLCHMVWBQR-UHFFFAOYSA-M diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)([O-])OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-M 0.000 claims description 116
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 claims description 55
- -1 2-ethyl Chemical group 0.000 claims description 43
- 125000004432 carbon atom Chemical group C* 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000000732 arylene group Chemical group 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 238000004617 QSAR study Methods 0.000 claims description 26
- 230000002887 neurotoxic effect Effects 0.000 claims description 26
- 231100000189 neurotoxic Toxicity 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 18
- 231100001260 reprotoxic Toxicity 0.000 claims description 18
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 17
- 125000003367 polycyclic group Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 16
- 239000007983 Tris buffer Substances 0.000 claims description 14
- 125000002950 monocyclic group Chemical group 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 13
- 229910019142 PO4 Inorganic materials 0.000 claims description 12
- 239000004305 biphenyl Substances 0.000 claims description 12
- 235000010290 biphenyl Nutrition 0.000 claims description 12
- 239000010452 phosphate Substances 0.000 claims description 12
- 102100033639 Acetylcholinesterase Human genes 0.000 claims description 11
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 11
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 11
- 125000006267 biphenyl group Chemical group 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 108010053652 Butyrylcholinesterase Proteins 0.000 claims description 9
- 102100032404 Cholinesterase Human genes 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N 1,4-Benzenediol Natural products OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Natural products C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 6
- 238000000302 molecular modelling Methods 0.000 claims description 6
- 229960001553 phloroglucinol Drugs 0.000 claims description 6
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 229930185605 Bisphenol Natural products 0.000 claims description 4
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 125000005156 substituted alkylene group Chemical group 0.000 claims description 4
- DSKYSDCYIODJPC-UHFFFAOYSA-N 2-butyl-2-ethylpropane-1,3-diol Chemical compound CCCCC(CC)(CO)CO DSKYSDCYIODJPC-UHFFFAOYSA-N 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- QWMUDOFWQWBHFI-UHFFFAOYSA-N hydroxy-imino-diphenoxy-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1OP(=O)(N)OC1=CC=CC=C1 QWMUDOFWQWBHFI-UHFFFAOYSA-N 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- JZODKRWQWUWGCD-UHFFFAOYSA-N 2,5-di-tert-butylbenzene-1,4-diol Chemical compound CC(C)(C)C1=CC(O)=C(C(C)(C)C)C=C1O JZODKRWQWUWGCD-UHFFFAOYSA-N 0.000 claims description 2
- OIEFULAZPZJRDR-UHFFFAOYSA-N 2-aminoethoxy-N,N-diphenylphosphonamidic acid Chemical compound NCCOP(N(C1=CC=CC=C1)C1=CC=CC=C1)(O)=O OIEFULAZPZJRDR-UHFFFAOYSA-N 0.000 claims description 2
- BRPSWMCDEYMRPE-UHFFFAOYSA-N 4-[1,1-bis(4-hydroxyphenyl)ethyl]phenol Chemical compound C=1C=C(O)C=CC=1C(C=1C=CC(O)=CC=1)(C)C1=CC=C(O)C=C1 BRPSWMCDEYMRPE-UHFFFAOYSA-N 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims description 2
- XCZKKZXWDBOGPA-UHFFFAOYSA-N phenyl-hydroquinone Natural products OC1=CC=C(O)C(C=2C=CC=CC=2)=C1 XCZKKZXWDBOGPA-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 2
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical group C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 24
- 239000010723 turbine oil Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 102000003914 Cholinesterases Human genes 0.000 description 12
- 108090000322 Cholinesterases Proteins 0.000 description 12
- 229920005862 polyol Polymers 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000001988 toxicity Effects 0.000 description 12
- 231100000419 toxicity Toxicity 0.000 description 12
- 229910052698 phosphorus Inorganic materials 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000000314 lubricant Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 8
- 239000010720 hydraulic oil Substances 0.000 description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 150000003077 polyols Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 150000004982 aromatic amines Chemical class 0.000 description 7
- 239000002199 base oil Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229940059574 pentaerithrityl Drugs 0.000 description 7
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- AWBGQVBMGBZGLS-UHFFFAOYSA-N butyrylthiocholine Chemical compound CCCC(=O)SCC[N+](C)(C)C AWBGQVBMGBZGLS-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000001177 diphosphate Substances 0.000 description 5
- 235000011180 diphosphates Nutrition 0.000 description 5
- 239000003063 flame retardant Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000001050 lubricating effect Effects 0.000 description 5
- 210000001428 peripheral nervous system Anatomy 0.000 description 5
- 150000003018 phosphorus compounds Chemical class 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OWICEWMBIBPFAH-UHFFFAOYSA-N (3-diphenoxyphosphoryloxyphenyl) diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=C(OP(=O)(OC=2C=CC=CC=2)OC=2C=CC=CC=2)C=CC=1)(=O)OC1=CC=CC=C1 OWICEWMBIBPFAH-UHFFFAOYSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940048961 cholinesterase Drugs 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 231100001096 no neurotoxicity Toxicity 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000005649 substituted arylene group Chemical group 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- BOSMZFBHAYFUBJ-UHFFFAOYSA-N tris(4-methylphenyl) phosphate Chemical compound C1=CC(C)=CC=C1OP(=O)(OC=1C=CC(C)=CC=1)OC1=CC=C(C)C=C1 BOSMZFBHAYFUBJ-UHFFFAOYSA-N 0.000 description 3
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010048650 Cholinesterase inhibition Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NUPSHWCALHZGOV-UHFFFAOYSA-N Decyl acetate Chemical compound CCCCCCCCCCOC(C)=O NUPSHWCALHZGOV-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- OIZXRZCQJDXPFO-UHFFFAOYSA-N Octadecyl acetate Chemical compound CCCCCCCCCCCCCCCCCCOC(C)=O OIZXRZCQJDXPFO-UHFFFAOYSA-N 0.000 description 2
- CGSLYBDCEGBZCG-UHFFFAOYSA-N Octicizer Chemical compound C=1C=CC=CC=1OP(=O)(OCC(CC)CCCC)OC1=CC=CC=C1 CGSLYBDCEGBZCG-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- HRKAMJBPFPHCSD-UHFFFAOYSA-N Tri-isobutylphosphate Chemical compound CC(C)COP(=O)(OCC(C)C)OCC(C)C HRKAMJBPFPHCSD-UHFFFAOYSA-N 0.000 description 2
- GTVWRXDRKAHEAD-UHFFFAOYSA-N Tris(2-ethylhexyl) phosphate Chemical compound CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC GTVWRXDRKAHEAD-UHFFFAOYSA-N 0.000 description 2
- ZGHUDSLVQAGWEY-UHFFFAOYSA-N [2-[bis(2-chloroethoxy)phosphoryloxymethyl]-3-chloro-2-(chloromethyl)propyl] bis(2-chloroethyl) phosphate Chemical compound ClCCOP(=O)(OCCCl)OCC(CCl)(CCl)COP(=O)(OCCCl)OCCCl ZGHUDSLVQAGWEY-UHFFFAOYSA-N 0.000 description 2
- 239000012445 acidic reagent Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- BNMJSBUIDQYHIN-UHFFFAOYSA-N butyl dihydrogen phosphate Chemical compound CCCCOP(O)(O)=O BNMJSBUIDQYHIN-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- DHEMFBSSQAFTOU-UHFFFAOYSA-N dibutyl 2-[bis(2-ethylhexoxy)phosphinothioylsulfanyl]butanedioate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)SP(=S)(OCC(CC)CCCC)OCC(CC)CCCC DHEMFBSSQAFTOU-UHFFFAOYSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 231100000584 environmental toxicity Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- ZAZKJZBWRNNLDS-UHFFFAOYSA-N methyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC ZAZKJZBWRNNLDS-UHFFFAOYSA-N 0.000 description 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 2
- 229940117969 neopentyl glycol Drugs 0.000 description 2
- YLYBTZIQSIBWLI-UHFFFAOYSA-N octyl acetate Chemical compound CCCCCCCCOC(C)=O YLYBTZIQSIBWLI-UHFFFAOYSA-N 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 2
- HQUQLFOMPYWACS-UHFFFAOYSA-N tris(2-chloroethyl) phosphate Chemical compound ClCCOP(=O)(OCCCl)OCCCl HQUQLFOMPYWACS-UHFFFAOYSA-N 0.000 description 2
- LORSVOJSXMHDHF-UHFFFAOYSA-N tris(4-tert-butylphenyl) phosphate Chemical compound C1=CC(C(C)(C)C)=CC=C1OP(=O)(OC=1C=CC(=CC=1)C(C)(C)C)OC1=CC=C(C(C)(C)C)C=C1 LORSVOJSXMHDHF-UHFFFAOYSA-N 0.000 description 2
- HUJOGFUFUMBXPL-UHFFFAOYSA-N (2-methylphenyl) dihydrogen phosphate Chemical compound CC1=CC=CC=C1OP(O)(O)=O HUJOGFUFUMBXPL-UHFFFAOYSA-N 0.000 description 1
- VDIFKDMFGPIVCQ-UHFFFAOYSA-N (2-tert-butylphenyl) diphenyl phosphate Chemical compound CC(C)(C)C1=CC=CC=C1OP(=O)(OC=1C=CC=CC=1)OC1=CC=CC=C1 VDIFKDMFGPIVCQ-UHFFFAOYSA-N 0.000 description 1
- VHYHRNYPVNFGNR-UHFFFAOYSA-N (3,5-ditert-butylphenyl)methanol Chemical compound CC(C)(C)C1=CC(CO)=CC(C(C)(C)C)=C1 VHYHRNYPVNFGNR-UHFFFAOYSA-N 0.000 description 1
- GBZVNKQWXLVYNG-UHFFFAOYSA-N (3-phosphonooxyphenyl) dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=CC(OP(O)(O)=O)=C1 GBZVNKQWXLVYNG-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- PIMNDJYXVOQVSP-UHFFFAOYSA-N 1-o-ethyl 10-o-hexyl decanedioate Chemical compound CCCCCCOC(=O)CCCCCCCCC(=O)OCC PIMNDJYXVOQVSP-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- CWPPDTVYIJETDF-UHFFFAOYSA-N 2,2,4-trimethylpentan-1-ol Chemical compound CC(C)CC(C)(C)CO CWPPDTVYIJETDF-UHFFFAOYSA-N 0.000 description 1
- SZSSMFVYZRQGIM-UHFFFAOYSA-N 2-(hydroxymethyl)-2-propylpropane-1,3-diol Chemical compound CCCC(CO)(CO)CO SZSSMFVYZRQGIM-UHFFFAOYSA-N 0.000 description 1
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PTJWCLYPVFJWMP-UHFFFAOYSA-N 2-[[3-hydroxy-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)COCC(CO)(CO)CO PTJWCLYPVFJWMP-UHFFFAOYSA-N 0.000 description 1
- QMIIYQVYBXUULW-UHFFFAOYSA-N 2-[hydroxy-(4-methylphenyl)methyl]phenol Chemical compound C1=CC(C)=CC=C1C(O)C1=CC=CC=C1O QMIIYQVYBXUULW-UHFFFAOYSA-N 0.000 description 1
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 1
- WEQAAFZDJROSBF-UHFFFAOYSA-M 2-butanoylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CCCC(=O)SCC[N+](C)(C)C WEQAAFZDJROSBF-UHFFFAOYSA-M 0.000 description 1
- OTKHZEOSBVSFCJ-UHFFFAOYSA-N 2-butylbutane-1,3-diol Chemical compound CCCCC(CO)C(C)O OTKHZEOSBVSFCJ-UHFFFAOYSA-N 0.000 description 1
- VNAWKNVDKFZFSU-UHFFFAOYSA-N 2-ethyl-2-methylpropane-1,3-diol Chemical compound CCC(C)(CO)CO VNAWKNVDKFZFSU-UHFFFAOYSA-N 0.000 description 1
- SPXWGAHNKXLXAP-UHFFFAOYSA-N 2-methylpentane-1,3-diol Chemical compound CCC(O)C(C)CO SPXWGAHNKXLXAP-UHFFFAOYSA-N 0.000 description 1
- GANZODCWZFAEGN-UHFFFAOYSA-L 2-nitro-5-sulfidobenzoate Chemical compound [O-]C(=O)C1=CC([S-])=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-L 0.000 description 1
- NZGQHKSLKRFZFL-UHFFFAOYSA-N 4-(4-hydroxyphenoxy)phenol Chemical compound C1=CC(O)=CC=C1OC1=CC=C(O)C=C1 NZGQHKSLKRFZFL-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- MBEDWQDNVFZYCN-UHFFFAOYSA-N 4-methylnonane-5,5-diol Chemical compound CCCCC(O)(O)C(C)CCC MBEDWQDNVFZYCN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- BYMMIQCVDHHYGG-UHFFFAOYSA-N Cl.OP(O)(O)=O Chemical compound Cl.OP(O)(O)=O BYMMIQCVDHHYGG-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- NEHDRDVHPTWWFG-UHFFFAOYSA-N Dioctyl hexanedioate Chemical compound CCCCCCCCOC(=O)CCCCC(=O)OCCCCCCCC NEHDRDVHPTWWFG-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000002430 Multiple chemical sensitivity Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical group OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- YOLFSLXHLNWPKG-UHFFFAOYSA-N [3-bis(2,6-dimethylphenoxy)phosphoryloxyphenyl] bis(2,6-dimethylphenyl) phosphate Chemical compound CC1=CC=CC(C)=C1OP(=O)(OC=1C(=CC=CC=1C)C)OC1=CC=CC(OP(=O)(OC=2C(=CC=CC=2C)C)OC=2C(=CC=CC=2C)C)=C1 YOLFSLXHLNWPKG-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LEKJTGQWLAUGQA-UHFFFAOYSA-N acetyl iodide Chemical compound CC(I)=O LEKJTGQWLAUGQA-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- VCCBEIPGXKNHFW-UHFFFAOYSA-N biphenyl-4,4'-diol Chemical group C1=CC(O)=CC=C1C1=CC=C(O)C=C1 VCCBEIPGXKNHFW-UHFFFAOYSA-N 0.000 description 1
- ZDWGXBPVPXVXMQ-UHFFFAOYSA-N bis(2-ethylhexyl) nonanedioate Chemical compound CCCCC(CC)COC(=O)CCCCCCCC(=O)OCC(CC)CCCC ZDWGXBPVPXVXMQ-UHFFFAOYSA-N 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- YRIBGSCJIMXMPJ-UHFFFAOYSA-N butyrylcholine Chemical compound CCCC(=O)OCC[N+](C)(C)C YRIBGSCJIMXMPJ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Chemical group 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- GHLKSLMMWAKNBM-UHFFFAOYSA-N dodecane-1,12-diol Chemical compound OCCCCCCCCCCCCO GHLKSLMMWAKNBM-UHFFFAOYSA-N 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 239000010705 motor oil Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N octadecanoic acid methyl ester Natural products CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002957 persistent organic pollutant Substances 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001955 polyphenylene ether Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- WLFXSECCHULRRO-UHFFFAOYSA-N pyridine-2,6-diol Chemical compound OC1=CC=CC(O)=N1 WLFXSECCHULRRO-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- QXJQHYBHAIHNGG-UHFFFAOYSA-N trimethylolethane Chemical compound OCC(C)(CO)CO QXJQHYBHAIHNGG-UHFFFAOYSA-N 0.000 description 1
- LLPMAOBOEQFPRE-UHFFFAOYSA-N tris(3,5-dimethylphenyl) phosphate Chemical compound CC1=CC(C)=CC(OP(=O)(OC=2C=C(C)C=C(C)C=2)OC=2C=C(C)C=C(C)C=2)=C1 LLPMAOBOEQFPRE-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M137/00—Lubricating compositions characterised by the additive being an organic non-macromolecular compound containing phosphorus
- C10M137/02—Lubricating compositions characterised by the additive being an organic non-macromolecular compound containing phosphorus having no phosphorus-to-carbon bond
- C10M137/04—Phosphate esters
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M105/00—Lubricating compositions characterised by the base-material being a non-macromolecular organic compound
- C10M105/08—Lubricating compositions characterised by the base-material being a non-macromolecular organic compound containing oxygen
- C10M105/32—Esters
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M137/00—Lubricating compositions characterised by the additive being an organic non-macromolecular compound containing phosphorus
- C10M137/12—Lubricating compositions characterised by the additive being an organic non-macromolecular compound containing phosphorus having a phosphorus-to-carbon bond
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M137/00—Lubricating compositions characterised by the additive being an organic non-macromolecular compound containing phosphorus
- C10M137/16—Lubricating compositions characterised by the additive being an organic non-macromolecular compound containing phosphorus having a phosphorus-to-nitrogen bond
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M2207/00—Organic non-macromolecular hydrocarbon compounds containing hydrogen, carbon and oxygen as ingredients in lubricant compositions
- C10M2207/28—Esters
- C10M2207/2805—Esters used as base material
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M2223/00—Organic non-macromolecular compounds containing phosphorus as ingredients in lubricant compositions
- C10M2223/02—Organic non-macromolecular compounds containing phosphorus as ingredients in lubricant compositions having no phosphorus-to-carbon bonds
- C10M2223/04—Phosphate esters
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M2223/00—Organic non-macromolecular compounds containing phosphorus as ingredients in lubricant compositions
- C10M2223/02—Organic non-macromolecular compounds containing phosphorus as ingredients in lubricant compositions having no phosphorus-to-carbon bonds
- C10M2223/04—Phosphate esters
- C10M2223/041—Triaryl phosphates
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M2223/00—Organic non-macromolecular compounds containing phosphorus as ingredients in lubricant compositions
- C10M2223/08—Organic non-macromolecular compounds containing phosphorus as ingredients in lubricant compositions having phosphorus-to-nitrogen bonds
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10N—INDEXING SCHEME ASSOCIATED WITH SUBCLASS C10M RELATING TO LUBRICATING COMPOSITIONS
- C10N2030/00—Specified physical or chemical properties which is improved by the additive characterising the lubricating composition, e.g. multifunctional additives
- C10N2030/06—Oiliness; Film-strength; Anti-wear; Resistance to extreme pressure
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10N—INDEXING SCHEME ASSOCIATED WITH SUBCLASS C10M RELATING TO LUBRICATING COMPOSITIONS
- C10N2030/00—Specified physical or chemical properties which is improved by the additive characterising the lubricating composition, e.g. multifunctional additives
- C10N2030/10—Inhibition of oxidation, e.g. anti-oxidants
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10N—INDEXING SCHEME ASSOCIATED WITH SUBCLASS C10M RELATING TO LUBRICATING COMPOSITIONS
- C10N2040/00—Specified use or application for which the lubricating composition is intended
- C10N2040/04—Oil-bath; Gear-boxes; Automatic transmissions; Traction drives
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10N—INDEXING SCHEME ASSOCIATED WITH SUBCLASS C10M RELATING TO LUBRICATING COMPOSITIONS
- C10N2040/00—Specified use or application for which the lubricating composition is intended
- C10N2040/06—Instruments or other precision apparatus, e.g. damping fluids
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10N—INDEXING SCHEME ASSOCIATED WITH SUBCLASS C10M RELATING TO LUBRICATING COMPOSITIONS
- C10N2040/00—Specified use or application for which the lubricating composition is intended
- C10N2040/12—Gas-turbines
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10N—INDEXING SCHEME ASSOCIATED WITH SUBCLASS C10M RELATING TO LUBRICATING COMPOSITIONS
- C10N2040/00—Specified use or application for which the lubricating composition is intended
- C10N2040/12—Gas-turbines
- C10N2040/13—Aircraft turbines
Definitions
- the present invention relates to the technical field of anti-wear additives used in oils such as oils for lubricating aircraft or aero-derivative turbines or hydraulic oils.
- Aircraft or aero-derivative turbine engines use synthetic lubricants generally comprising an ester base and a variety of anti-wear additives from the organophosphate family such as triarylphosphates.
- the most widely used antiwear additive commercially is tricresylphosphate (TCP), which has unique antiwear properties that can be considered unique to this day. Its tri-arylphosphates analogues are also valuable antiwear additives.
- Leaks of lubricants, especially those containing tricresylphosphate or one of its tri-arylphosphate analogues, in the air of aircraft cabins can be caused by worn or defective seals, or even under normal conditions of use by passage. lubricants in the air intended for cabin pressurization. These repeated leaks are explained (Michaelis S. et al. Public Health Panorama 2017, 3, 2, p.198-211) as being due to pressure variations between the bearing chamber and the air circuit exerted by normal conditions. operation (increase in engine power, take-off, etc.). Under certain circumstances, the leak can become very large, generally following a breakage of a bearing in the turbine, which leads to a smoke event, or white fog visible in the cabin.
- Aerotoxic syndrome is a pathological condition combining physical and neurological symptoms, caused by the short and long term effects of exposure to aircraft cabin air, contaminated with hydraulic oils or engine oils or any of the above. other organic pollutant present in the form of gas and / or aerosols. Symptoms reported are generally non-specific, and cabin air quality studies indicate levels of contaminants that are below exposure limits and not harmful to human health, the difficulty being to continuously and continuously measure. service of the emanations of oils, by definition non-carbonated, conveyed in the air, settling and concentrating, episodically, at different locations of the aircraft (Kasper Solbu et al. J. Environ. Monit. 2011, 13, 1393 ).
- Aero-derived turbines operate identically to aircraft turbines and use lubricants of similar composition, especially in terms of anti-wear agents.
- organophosphate antiwear additives such as letricresylphosphate (TCP), especially its tri-ortho-cresylphosphate (ToCP) isomer
- TCP tri-ortho-cresylphosphate
- ToCP tri-ortho-cresylphosphate
- TCP poisoning leads to a pathology called Organophosphate-induced delayed neuropathy (OPIDN), the mechanism of which has been widely studied.
- OPIDN Organophosphate-induced delayed neuropathy
- TCP is also known to be reprotoxic.
- TCP is also known to be reprotoxic
- anti-wear additives alternative to tricresylphosphate and its tri-arylphosphate analogues for which an absence of neurotoxicity and reprotoxicity would be established would be advantageous and would allow the level to be increased. safety in aviation and other aero-derivative applications.
- Patent application US2016 / 0002565 describes a tricresylphosphate-free turbine oil which comprises at least one base oil, at least one alkylpolyglycoside and a phenolic derivative such as 3,5-di-tert-butyl-hydroxytoluene.
- Replacing tricresylphosphate with the phenolic derivative contributes to the prevention of aerotoxic syndrome when this oil is used in aircraft turbines.
- the use of such an oil in aircraft turbines does not seem to be able to provide the same efficiency as that of the oil containing tricresylphosphate which it is supposed to replace, on the one hand because the formulation described does not. comprises no agent exhibiting an anti-wear effect making it possible to replace that of TCP, and on the other hand because the formulation comprises alkylpolyglycosides which are thermosensitive.
- Patent application WO2010 / 149690 describes the reduced effect on butyrylcholinesterase, compared with TCP in particular, of specific triarylphosphates in which the phenyl groups are substituted by one to three isopropyl or fenf-butyl groups. These inhibition results suggest a possible reduction in the neurotoxicity associated with these compounds compared to that observed for TCP. However, the simple demonstration of a limited effect on a single cholinesterase does not seem sufficient to guarantee a level of safety sufficient for the expectations of aviation.
- toxicity is a fairly broad concept which includes in particular:
- - acute toxicity is the toxicity induced, in a short period of time (eg 24 h), by the administration of a single dose (possibly massive) or of several doses acquired within this period of time of a product or mixture toxic (natural or chemical),
- - neurotoxicity which is the ability of a substance or compound to induce harmful effects in the nervous system of a mammal, such as humans.
- a compound may, for example, not be reprotoxic, show no sign of acute toxicity, or even show no CMR character (carcinogenic, mutagenic, or toxic for reproduction) on human health and yet be highly neurotoxic ( Or vice versa).
- V6 compound tetrakis (2-chloroethyl) dichloroisopentyldiphosphate
- WO2015 / 026566 describes a lubricant comprising: (i) a large amount (50% or more by mass relative to the total mass) of a natural or synthetic base oil and (ii) a small amount of an aryl biphosphate ester of formula (I) as antiwear additive and which may correspond, for example, to resorcinol bis (diphenylphosphate).
- ISA / EP Document EP 0612 837 describes a lubricant based on polyphenylene ether comprising an anti-wear additive comprising a hydrocarbyl bis (dihydrocarbylphosphate) compound, such as resorcinol bis (diphenylphosphate).
- an anti-wear additive comprising a hydrocarbyl bis (dihydrocarbylphosphate) compound, such as resorcinol bis (diphenylphosphate).
- Document US 2001/306530 describes a composition comprising a base oil which may be a polyol ester and a phosphorus compound.
- the exemplified phosphorus compound comprises a diphosphorus compound ("tetraphenyl (m-phenylene) bisphosphate") and tricresylphosphate.
- polyphosphorus compounds in particular polyphosphorus aryl compounds, which exhibit both satisfactory anti-wear and thermal stability properties, or even improved, exhibit greatly reduced neurotoxicity compared with that of anti- monophosphate wear such as TCP or even zero.
- These polyphosphorus compounds can therefore be advantageously used in oils, in particular for lubricating aircraft or aerodrive turbines, to reduce and / or prevent the neurotoxicity of oils and in particular turbine oils.
- the present invention relates to the use of at least one anti-wear additive in an oil, said at least anti-wear additive comprising at least one polyphosphorus compound of formula (I) wherein each of R1, R2, R3 and R4 is independently selected from: an alkyl group, an O-alkyl group, an aryl group, an or O-aryl group,
- A is a divalent group selected from a linear alkylene group comprising from 7 to 36 carbon atoms or branched comprising from 6 to 36 carbon atoms, a monocyclic, polycyclic or polyaromatic arylene group or an aralkylene group, each of Xi and X2 is independently a single bond, an oxygen atom or a nitrogen atom, and n is an integer between 1 and 5, to reduce and / or prevent the neurotoxicity of said oil.
- said oil and / or said at least antiwear additive does not comprise tricresylphosphate or one of its triarylphosphate analogues.
- the polyphosphorus compounds of formula (I) can thus be used to obtain an oil which is non-neurotoxic or has reduced neurotoxicity.
- the compounds of formula (I) exhibit valuable anti-wear properties, which can be comparable to those of tricresylphosphate or its triarylphosphate analogues. They also present a very low or even zero risk level in terms of neurotoxicity and thus reduce and / or prevent the neurotocixity of the oil in which they are incorporated.
- the invention also relates to the use of at least one antiwear additive in an oil, said at least antiwear additive comprising at least one polyphosphorus compound of formula (I)
- each of R1, R2, R3 and R4 is independently selected from: an alkyl group, an O-alkyl group, an aryl group, an or O-aryl group.
- A is a divalent group selected from an alkyl group comprising from 7 to 36 carbon atoms or branched comprising from 6 to 36 carbon atoms, a monocylic, polycyclic or polyaromatic arylene group or an aralkylene group, each of Xi and X 2 is independently a single bond, an oxygen atom or a nitrogen atom, and n is an integer between 1 and 5, for the prophylaxis of aerotoxic syndrome, preferably in the event of a smoke event.
- said oil and / or said at least antiwear additive does not comprise tricresylphosphate or one of its triarylphosphate analogues.
- said oil and / or said at least antiwear additive does not comprise tricresylphosphate or one of its triarylphosphate analogues.
- the term “include” and its derivatives should be understood as not limiting and not excluding the presence of other components or steps.
- the term “comprising” may be understood as “consisting essentially of” or “consisting of”.
- FIG.1 presents molecules resulting from modeling work using spherical harmonics: the compounds in the upper row belong to cluster 1, the compounds in the lower row belong to cluster 3; and
- FIGs. 2 to 9 are tables grouping together the results of the tests carried out in order to study the neurotoxicity of phosphorus-based compounds according to the prior art (comparative compounds) and of compounds of formula (I) according to the invention ( compounds 1 to 10).
- a first object of the invention is the use of at least one antiwear additive in an oil, said at least antiwear additive comprising at least one polyphosphorus compound of formula (I) wherein each of R1, R2, R3 and R4 is independently selected from: an alkyl group, an O-alkyl group, an aryl group, an or O-aryl group,
- A is a divalent group selected from an alkylene group comprising from 7 to 36 carbon atoms or branched comprising from 6 to 36 carbon atoms, a monocylic, polycyclic or polyaromatic arylene group or an aralkylene group, each of Xi and X2 is independently a single bond, an oxygen atom or a nitrogen atom, and n is an integer between 1 and 5, to reduce and or prevent the neurotoxicity of said oil, preferably a turbine oil.
- “By reducing” the neurotoxicity of an oil is meant that the compound (s) of formulas (I) according to the invention are suitable and / or configured (s) for reducing the neurotoxicity of an oil in which they are included, namely by their presence (generally in the majority), in particular compared to other generally neurotoxic conventional anti-wear compounds, the compound (s) of formula (I) make it possible to lower / reduce the neurotoxicity of an oil and of obtain a non-neurotoxic oil or at least with reduced toxicity.
- Preventing the neurotoxicity of an oil is understood to mean that the compound (s) of formula (I) make it possible to prevent the oil from being considered as neurotoxic and / or to prevent the appearance of neurotoxic symptoms in a. mammal, such as a human being or an animal which would be in contact with said oil; these neurotoxic symptoms can, for example, reach the central nervous system (CNS) and present the following effects: headache, loss of appetite, drowsiness, mood and personality disorders, cognitive impairment ( learning and concentration), or affect the peripheral nervous system (PNS) and exhibit the following effects: motor impairment such as weakness, tremors, incoordination, convulsions, etc. or sensory damage, such as hearing loss, color vision, tinnitus, loss of balance, etc. ; these effects may or may not be reversible depending on the degree of acute or chronic exposure of the mammal.
- CNS central nervous system
- PNS peripheral nervous system
- Neurotoxicity means the ability of a substance or compound to induce adverse effects in the nervous system of a mammal, such as humans.
- ISA / EP nervous system is divided into central nervous system (CNS) and peripheral nervous system (PNS).
- the CNS is located in the cranial box and the spine. It includes the brain, brainstem, and spinal cord. Its role is to receive, record and interpret the signals which reach it from the periphery. It then organizes the response to be sent.
- the PNS is made up of nerve ganglia, sensory nerves responsible for transmitting sensations to the brain, such as pain, and motor nerves responsible for movement by stimulating muscles. They circulate information between the CNS and the organs.
- a neurotoxic substance or compound usually acts by disrupting or paralyzing nerve impulses, in particular by acting on synaptic transmitters or receptors or on the enzymes which act on these synaptic transmitters or receptors, such as cholinesterases.
- a cholinesterase is an enzyme that catalyzes the hydrolysis reaction of an ester of choline (acetylcholine, butyrylcholine) into choline and acetic or butyric acid. In physiology, this reaction is necessary to allow cholinergic receptors to return to their resting state after activation.
- the Applicant has demonstrated the non-neurotoxicity of the specific compounds of formula (I) both by in vitro experimental tests relating to cholinesterases and by modeling tests (3D molecular modeling by spherical harmonics and modeling by QSAR for neurotoxicity and for reprotoxicity).
- the 50% inhibitory concentration of said at least compound of formula (I) on the biological activity of an acetylcholinesterase (AChE) enzyme, called ICsohAChE is greater than or equal to 15 mg / L, preferably greater than or equal to 16 mg / L and the activity on a butyrylcholinesterase enzyme, called IC 50 eqBuChE is greater than or equal to 15 mg / L, in particular greater than or equal to 50 mg / L, preferably equal to or greater than 55 mg / L, in in particular equal to or greater than 60 mg / L and typically equal to or greater than 70 mg / L.
- AChE acetylcholinesterase
- a value greater than or equal to 15 mg / L for ICsohAChE includes the following values and all the intervals between these values: 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30 ; 31; 32; 33; 34; 35; 36; 37; 38; 39; 40, etc.
- a value greater than or equal to 15 mg / L for IC50 eqBuChE includes the following values and all the intervals between these values: 15; 16; 17 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30 ; 31; 32; 33; 34; 35; 36; 37; 38; 39 40; 45; 50; 55; 60; 65; 70; 75; 80; 85; 90; 95; 100; 105; 110; 115; 120; 125; 130; 135,140; 145; 150; 155; 160; etc.
- the compound (s) of formula (I) belong to Cluster 3 determined according to molecular modeling by spherical harmonics as described in the publication “Benchmarking of HPCC: A novel 3D molecular representation combining shape and pharmacophoric descriptors for efficient molecular similarity assessments” , Karaboga et al. 2013 Journal of Molecular Graphics and Modeling 41; 20-30.
- the compound (s) of formula (I) exhibit a value in percentage (%) by QSAR modeling (quantitative structure activity relationship) (standing for “Quantitative Structure Activity Relationship”) or equal to 0.70%, preferably less than or equal to 0.50% and typically less than or equal to 0.15% for the measurement of neurotoxicity (neurotoxic QSAR) and less than or equal to 1.5%, preferably less or equal to 1.15% and typically less than or equal to 0.55% for the measurement of reprotoxicity (reprotoxic QSAR).
- a value less than or equal to 0.70% for neurotoxic QSAR modeling includes the following values and all the intervals between these values: 0.70; 0.69 0.68; 0.67; 0.66; 0.65; 0.64; 0.63; 0.62; 0.61; 0.60; 0.59; 0.58; 0.57; 0.56; 0.55; 0.54
- a value less than or equal to 1.50% for reprotoxic QSAR modeling includes the following values and all the intervals between these values: 1.50 1.48; 1.46; 1, 44; 1.42; 1, 40; 1.38; 1.36; 1.34; 1.32; 1.30; 1.28; 1.26; 1.24; 1.22; 1.20
- the compounds of formula (I) according to the invention exhibit a level of risk in terms of neurotoxicity which is very low and which generally corresponds to a score of 0 or to a score of 1 (very low or no risk of neurotoxicity) , preferably at a score of 0.
- the level of risk as defined above and also illustrated in the experimental part below is very exhaustive and includes all the data obtained via the various tests on neurotocity described above and therefore includes both tests in vitro as 3D modeling tests.
- the risk level takes into account all of the following tests:
- oil denotes any organic substance, in particular any hydraulic or turbine oil, liable to create pollution in the form of gas and / or aerosol in the cabin.
- the oil is selected from the group consisting of aircraft or aero-derivative oils, helicopter transmission oils, and weapon fluids.
- the oil is an oil for aircraft turbines or aero-derivatives.
- the oil is preferably used to lubricate aircraft or air-derivative turbines.
- the groups R1, R2, R3 and R4 of the polyphosphorus compounds of formula (I) according to the invention is independently chosen from: an alkyl group, an O-alkyl group, an aryl group, a group or O-aryl.
- alkyl group denotes a linear or branched saturated hydrocarbon group comprising (unless otherwise mentioned) from 1 to 36 carbon atoms (C1 to C36), more preferably from 1 to 18 carbon atoms ( Ci to Cie), in particular from 1 to 10 carbon atoms (Ci to C10), and typically from 1 to 4 carbon atoms (Ci to C4).
- alkyl groups according to the invention there may be mentioned in particular the methyl, ethyl, propyl, isopropyl, n-butyl and tert-butyl groups.
- the alkyl group may optionally be a substituted alkyl group.
- substituted alkyl group denotes a linear or branched saturated hydrocarbon chain as defined above and substituted, at the level of one or more of its atoms, by one or more radicals chosen from: a hydroxyl radical OH, an amine NH 2 or primary amine NHR radical with R alkyl or aryl group, preferably an OH hydroxyl radical.
- the alkyl group cannot be substituted with a halogen, such as chlorine.
- O-alkyl group is meant an alkyl group as defined above, connected to the rest of the molecule (here, generally the phosphorus atom) through an oxygen atom.
- aryl group denotes a monovalent organic group derived from an aromatic hydrocarbon comprising from 5 to 14 carbon atoms and corresponds for example to an aromatic hydrocarbon ring (such as a phenyl) or two fused aromatic hydrocarbon rings (such as than a naphthyl).
- an aryl group can be substituted or unsubstituted.
- a “substituted aryl group” denotes a ring or two fused aromatic hydrocarbon-based rings substituted at the level of one or more of its atoms, by at least one substituent consisting of C 1 -C 18 alkyl groups, the hydroxyl group
- RECTIFIED SHEET (RULE 91) ISA / EP OH, an amine NH2 group or a primary amine NHR with R C1-C6 alkyl group or aryl, preferably by C 1 -C 18 alkyl groups , such as a methyl group, or the hydroxyl group OH.
- O-aryl group is meant an aryl group, as defined above, linked to the rest of the molecule through an oxygen atom.
- each alkyl group is an alkyl group comprising from 1 to 22 carbon atoms (C1 to C22), preferably from 1 to 18 carbon atoms (C1 to Cis), in particular from 1 to 10 carbon atoms. carbon (Ci to C10) and typically from 1 to 4 carbon atoms (Ci to C4).
- At least one of R1, R2, R3 and R4 is aryl or O-aryl.
- at least two of R1, R2, R3 and R4 are aryl or O-aryl groups.
- R1, R2, R3 and R4 are four aryl or O-aryl groups, such as O-phenyl or is a substituted O-aryl group, such as O-dimethylphenyl.
- R1, R2, R3 and R4 are phenyl.
- R1, R2, R3 and R4 are phenyl groups.
- R1, R2, R3 and R4 are unsubstituted phenyl groups or phenyl groups substituted with at least one methyl group, preferably two methyl groups (such as 2,6-dimethylphenyl).
- R1, R2, R3 and R4 are O-phenyl.
- R1, R2, R3 and R4 are O-phenyl groups.
- R1, R2, R3 and R4 are unsubstituted O-phenyl groups or O-phenyl groups substituted with at least one methyl group, preferably substituted with two methyl groups (such as 2,6-dimethylphenyl).
- a of formula (I) according to the invention can be chosen from an alkylene group, an arylene group or an aralkylene group.
- alkylene group denotes a divalent linear saturated hydrocarbon group comprising (unless otherwise stated) from 7 to 36 carbon atoms (C7 to C 36 ), preferably 7 to 22 carbon atoms (C7 to C22), preferably from 7 to 18 carbon atoms (C7 to Cis), or a branched saturated hydrocarbon divalent group comprising (unless otherwise stated) preferably from 6 to 36 carbon atoms (Ob to C 36 ), preferably 6 to 22 carbon atoms (Ob to C 22 ), preferably from 6 to 18 carbon atoms (C 6 to Cis), in particular from 6 to 12 carbon atoms (C 6 to C12).
- An alkylene group may be unsubstituted or may optionally be.
- substituted alkylene group denotes an alkylene group as defined above substituted at the level of one or more of its atoms, by at least one substituent chosen from the group consisting of the linear or branched C 1 to 4 alkyl group.
- Cis the hydroxyl group OH; an NH2 amine or NHR primary amine group with R alkyl - (as defined above) or aryl (as defined above); an O-phosphate group, such as the O- group
- S and the alkylene group substituted with one O-phosphate moiety may be a 1,3- (2-ethyl 2- [methyl O- diphenyl]) propyl.
- arylene group denotes a monocyclic or polycyclic aromatic carbon group derived from an aromatic hydrocarbon and including at least two (divalent) anchoring points which are connected to X1 and X2 disposed on the aromatic ring (s) (both anchor points can be on the same ring of the polycyclic group).
- Each aromatic or polyaromatic ring can comprise from 5 to 14 atoms.
- An arylene group can correspond, for example, to an aromatic hydrocarbon ring (such as a phenylene), to two fused aromatic hydrocarbon rings (such as a naphthalene) or to two aromatic hydrocarbon rings linked by a covalent bond between two distinct atoms each belonging to to one of the cycles.
- the aromatic rings can optionally be interrupted by one or more heteroatoms which can in particular be chosen from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom, preferably consisting of by an oxygen atom or a sulfur atom.
- the arylene group does not include a nitrogen atom internal to the monocyclic or polycyclic aromatic carbon group.
- the arylene group cannot correspond, for example, to a pyridine or to a pyrimidine.
- Each ring can be unsubstituted or can be substituted to form a "substituted arylene group".
- the substituted arylene group may correspond to an O-diphenylphosphate radical may correspond to a 1,3- (5 O- [(diphenyl) phosphate)] phenyl group.
- arylene group is a polycyclic group in which at least two rings are linked by at least one covalent bond between two distinct atoms each belonging to
- A is or comprises a monocyclic arylene group such as a phenylene, or a thiophene derivative
- Xi and X2 are preferably diametrically opposed, in particular in position 1, 4 when the monocyclic arylene group comprises 6 carbon atoms (such as phenylene) .
- A is preferably a 1,4-phenyl group, optionally substituted.
- X1 and X2 are not in the ortho or meta position unless at least one and preferably all of the groups among R1, R2, R3 and R3 are O-phenyl groups substituted with two groups methyls, in particular in position 2,6. In this case, X1 and X2 can be in the meta position.
- A is or comprises a polycyl group, or a polyaromatic group comprising for example two fused rings, such as the naphthalene group
- X1 and X are preferably diametrically opposed in order to maximize the distance between X1 and X.
- X1 andX2 are not in the ortho or para position (in particular in the 1, 3 position), but can be in the 1,4 or 2,7 position.
- group A does not include electron-withdrawing groups or atoms, such as chlorine, carbonyl functions (aldehyde, carboxylic acid, C (O) -O), one or more internal nitrogen in the monocycle or polycyclic carbon group. (pyridine or pyrimidine). Group A therefore cannot be a pyridine or a pyrimidine.
- polycyclic arylene groups mention may in particular be made of 4,4'-biphenyl, 4,4'-diphenylthioether, 4,4'-diphenylether, 4,4'-diphenylphenylethylidene, 4,4'- dimethyldiphenylmethylidene, 4,4'-diphenylsulfone, 4,4'benzophenone, 2,2'benzophenone, 1,4-naphthalene, 1,3-naphthalene, 2,7-naphthalene, 2,6- anthracene, 9,10-anthracene and phenanthrene.
- aralkylene group is meant an alkyl group covalently bonded to an aryl group and comprising two (divalent) anchor points located on the alkyl group and / or on the aryl group.
- an “aralkylene” group may or may not be substituted.
- substituted aralkylene denotes an aralkylene group as defined above substituted, at the level of a
- aralkylene groups mention may in particular be made of the 4,4'- [diphenyl (dimethyl) methylidene] group and the 4,4'-diphenylhexafluoropropane group.
- A is selected from the group consisting of a 1,4-phenyl group, a 4,4'-biphenyl group, a 4,4'-diphenylthioether group, a 4,4'-diphenyl ether group, a 1,3- (5 0 - [(diphenyl) phosphate)] phenyl group, 1,3- (2-ethyl 2-butyl) propyl group, 1,3- (2-ethyl 2- [methyl 0- diphenylphosphate]) propyl, a 4,4'- [diphenyl (dimethyl) methylidene] group, a 2,2'-benzophenone group, a 2,7-naphthalene group, a 1,2-ethyl group, a 4,4 group '- [diphenylphenylethylidene], a 4,4'-diphenylsulfone group, a 4,4'-diphenylhexafluoropropane group
- A is selected from the group consisting of a 1,4-phenyl group, a 4,4'-biphenyl group, a 4,4'-diphenylthioether group, a 4,4'-diphenyl ether group, a 1,3- (5 0 - [(diphenyl) phosphate)] phenyl group, a 1,3- (2-ethyl 2-butyl) propyl group, a 1,3- (2-ethyl 2- [methyl 0 -diphenylphosphate]) propyl, a 4,4'- [diphenyl (dimethyl) methylidene] group, a 2,2'-benzophenone group, a 2,7-naphthalene group and a 1,2-ethyl group.
- A is selected from the group consisting of a 1,4-phenyl group, a 4,4'-biphenyl group, a 4,4'-diphenylthioether group, a 4,4'-diphenyl ether group. , a 1, 3- (5 0 - [(diphenyl) phosphate)] phenyl group, a 1, 3- (2-ethyl 2-butyl) propyl group, a 1,3- (2-ethyl 2- [methyl 0-diphenylphosphate]) propyl
- A is selected from the group consisting of a 4,4'-diphenylthioether group, a 4,4'-diphenyl ether group, a 1,3- (5 0 - [(diphenyl) phosphate)] phenyl group, a group 1,3- (2-ethyl 2-butyl) propyl, a 1,3- (2-ethyl 2- [methyl 0-diphenylphosphate]) propyl group
- A is an optionally substituted alkylene group, a substituted monocyclic arylene group or a polycyclic arylene group in which at least two rings are linked by at least one covalent bond between two distinct atoms each belonging to one of the rings, the covalent bond between the two rings being interrupted by at least one heteroatom or heteroatomic group.
- halogen atom denotes (unless otherwise indicated) an atom chosen from the group consisting of chlorine, bromine, fluorine and iodine.
- Each of Xi and X 2 is independently selected from the group consisting of a single bond, an oxygen atom and a nitrogen atom, preferably a single bond or an oxygen atom.
- Xi and X 2 are two oxygen atoms; in other embodiments, Xi and X 2 are two nitrogen atoms; finally, in last embodiments, one of Xi andX 2 is an oxygen atom and the other of Xi and X 2 is a nitrogen atom.
- Xi or X 2 is a nitrogen atom, it may be in the form of an NH group or an NR group, R being an alkyl or aryl group.
- N is an integer between 1 and 5.
- n can in particular be equal to 1, 2, 3, 4 or 5.
- “n” is equal to 1.
- a polyphosphorus compound denotes at least one among the oligomers comprising 1 to 5 units -XI-AX 2 -P (O) R4-, or any mixture of at least two of these.
- it may be a mixture of oligomers comprising 1 to 3 units -XI-AX 2 -P (0) R4-
- n 1.
- the polyphosphorus compounds used according to the invention are aryl diphosphates, that is to say they are such that Xi and X 2 are two oxygen atoms, and each of R1, R2, R3 and R4 is an O-aryl group (as defined above), optionally substituted for example by two methyl groups
- the Applicant has demonstrated the non-toxicity, in particular the non-neurotoxicity, or even the non-reprotoxicity, of the polyphosphorus compounds of formula (I).
- polyphosphorus compounds in particular aryl diphosphates
- the polyphosphorus compounds exhibit an anti-wear efficiency at least as advantageous as that obtained with conventional anti-wear additives such as TCP.
- said oil and / or said at least antiwear additive does not comprise tricresylphosphate or one of its triarylphosphate analogues.
- an oil or anti-wear agent not comprising tricresylphosphate is meant an oil or an anti-wear agent in which / in which the amount of tricresylphosphate, regardless of its type of substitution (ortho, meta, para) is lower than the detection limit of conventional analysis techniques such as gas chromatography coupled with mass spectrometry for example.
- a suitable technique for the detection of tricresylphosphate in an oil is described, for example, in De Nola G. et al. J. Chromatogr. In 2008; 7200 (2), p.211-216.
- the oil used according to the invention or the antiwear agent used according to the invention substantially does not include, preferably does not include, any aryl monophosphate antiwear additive, whatever. 'it be. In some embodiments, the oil used according to the invention or the antiwear agent used according to the invention substantially does not include, preferably does not include, an organophosphate antiwear additive other than the additive (s). polyphosphorus compounds.
- the oil used according to the invention or the antiwear agent used according to the invention substantially does not include, preferably does not include, any antiwear additive other than the compound additive (s). polyphosphorus.
- the antiwear agent according to the invention of general formula (I) represents, by mass, relative to the total mass of the antiwear agents present in the oil, from 50% to 100%, preferably from 80% to 100%, and in particular from 90% to 100% and typically 100%.
- 50% to 100% is meant the following values or any interval between these values: 50; 55; 60; 65; 70; 75; 80; 85; 90; 95; 100.
- polyphosphorus compound present in the oil used according to the invention is chosen from the group consisting of:
- DPP diphenylphosphate
- polyphosphorus compound present in the oil used according to the invention is chosen from the group consisting of:
- polyphosphorus compound present in the oil used according to the invention is chosen from the group consisting of:
- polyphosphorus compound present in the oil used according to the invention is chosen from the group consisting of:
- Polyphosphorus compounds are present in the oil used in the present invention in an amount such as those conventionally used in the art. For example, they can be used in an amount of 0.1 to 10% by weight, preferably 0.5 to 5% by weight, based on the total weight of the oil.
- the oil used according to the invention can include all of the conventional constituents and additives known in the art for this type of oil.
- the oil used according to the invention preferably comprises an ester base, at least one amino antioxidant, and at least one polyphosphorus anti-wear additive of formula (I).
- the oil used according to the invention also includes at least one other additive.
- the at least one other additive can in particular be chosen from the group consisting of lubricating agents, other anti-wear additives, antioxidants, inhibitors
- RECTIFIED SHEET (RULE 91) ISA / EP corrosion agents, passivators, viscosity index improvers, detergents or dispersing agents, anti-foaming agents, surfactants, blowing agents, tackifying agents, stabilizers, bulking agents, agents stabilization against hydrolysis, additives adapted to extreme pressures, pigments and agents that mask odors.
- Such additives and agents are well known to those skilled in the art and are commonly available commercially.
- the ester base is a conventional ester base, well known in the art. It is typically a synthetic oil which can be chosen from esters of monoalcohol or polyol, preferably polyol, with a mono or dicarboxylic acid reagent.
- Particularly suitable polyols are neo-polyols such as neopentylglycol, 2-ethyl 2-methylpropane 1,3-diol, trimethylolethane, trimethylolpropane, trimethylolbutane and mono-, di- or tri-pentaerythritol.
- neo-polyols such as neopentylglycol, 2-ethyl 2-methylpropane 1,3-diol, trimethylolethane, trimethylolpropane, trimethylolbutane and mono-, di- or tri-pentaerythritol.
- R (OH) p in which R is an optionally substituted linear, branched or cyclic aliphatic hydrocarbon group and p is an integer greater than or equal to 2.
- the polyol can be chosen from the group consisting of 2-ethyl-1,3- hexanediol, 2-propyl-3,3-heptanediol, 2-butyl-1,3-butanediol, 2,4-dimethyl-1,3-butanediol, ethylene glycol, propylene glycol and polyalkylene glycols.
- Particularly suitable mono-alcohols are neo-alcohols such as 2,2,4-trimethylpentanol and 2,2-dimethylpropanol.
- the monoalcohol can be chosen from the group consisting of methyl, butyl, isooctyl and octadecyl alcohols.
- the carboxylic acid reagent used to form the ester with the polyol or the monoalcohol can be chosen from optionally substituted aliphatic carboxylic acids comprising one or two carboxylic acid functions or any of their mixtures. Those skilled in the art will know how to select the carboxylic acids to be used depending on the properties desired for the ester and the monoalcohol or polyol used.
- ester bases which may be contained in an oil used according to the invention, mention may be made of monoesters of octyl acetate, decyl acetate, octadecyl acetate, methyl myristate or stearate. of butyl, of methyl oleate, as well as the polyesters of dibutyl phthalate, di-octyl adipate, di-2-ethylhexyl azelate and ethylhexyl sebacate.
- the polyol ester base oil can be an oil prepared from technical pentaerythritol or trimethylol propane and a mixture of carboxylic acids having 4 to 12 carbon atoms.
- Technical pentaerythritol is a mixture which comprises from about 85% to 92% by weight of monopentaerythritol and from 8% to 15% by weight of dipentaerythritol.
- a conventional commercial technical pentaerythritol contains about 88% by weight of monopentaerythritol and about 12% by weight of dipentaerythritol, based on the total weight of said base oil of the ester type.
- Technical pentaerythritol may also contain some amount of tri- and tetra-pentaerythritols which are usually formed as by-products during the production of technical pentaerythritol.
- Aromatic amine antioxidants are well known in the art and can be monomeric or polymeric aromatic amine antioxidants, belonging to the family of aromatic amines and / or phenolic compounds.
- the monomeric aromatic amine antioxidants can comprise in particular at least one diphenylamine which is unsubstituted or substituted with at least one hydrocarbon group, at least one naphthylphenylamine which is unsubstituted or substituted with at least one hydrocarbon group, at least one phenothiazine which is unsubstituted or substituted with at least one. hydrocarbon group, or any mixture thereof.
- the hydrocarbon groups substituting for the amines are C 1 -C 30 alkyl groups, or styrene.
- Polymeric aromatic amine antioxidants are the polymerization products of aromatic amine antioxidants as defined above, either with each other or in the presence of a different comonomer. Examples of oligomeric or polymeric aromatic amine antioxidants which can be used in turbine oils according to the invention are described in particular in patent applications FR 2 924 122 and WO 2009/071857.
- the present invention can thus relate to a process for the manufacture of a non-neurotoxic oil or one exhibiting greatly reduced neurotoxicity (in comparison with oils based on tricresylphosphate and its analogues or based on other neurotoxic phosphorus compounds) used in particular.
- for lubricating devices / machines, such as aircraft turbines or air-derivatives comprising the following step: incorporating into a base oil, such as an ester oil, at least one anti-wear agent, characterized in that said at least antiwear agent is selected from at least one polyphosphorus compound of formula (I) wherein each of R1, R2, R3 and R4 is independently selected from: an alkyl group, an O-alkyl group, an aryl group, an or O-aryl group,
- A is a divalent group selected from a linear alkylene group comprising from 7 to 36 carbon atoms or branched comprising from 6 to 36 carbon atoms, a monocyclic, polycyclic or polyaromatic arylene group or an aralkylene group, each of X and X is independently a single bond, an oxygen atom or a nitrogen atom, and
- ISA / EP n is an integer between 1 and 5, and presenting in particular a level of risk in terms of neurotoxicity of 0.
- Another subject of the invention relates to the use of at least one anti-wear additive in an oil, said at least anti-wear additive comprising at least one polyphosphorus compound of formula (I) wherein each of R1, R2, R3 and R4 is independently selected from: an alkyl group, an O-alkyl group, an aryl group, an or O-aryl group,
- A is a divalent group selected from an alkylene group comprising from 7 to 36 carbon atoms or branched comprising from 6 to 36 carbon atoms, a monocylic, polycyclic or polyaromatic arylene group or an aralkylene group, each of Xi and X2 is independently a single bond, an oxygen atom or a nitrogen atom, and n is an integer between 1 and 5, for the prophylaxis of aerotoxic syndrome, preferably in the event of a smoke event.
- the pathology designated by the terms "aerotoxic syndrome” is a pathology comprising at least in part the same neurological and reproductive symptoms as those observed in airplanes for the aerotoxic syndrome, but which is contracted by exposure.
- organophosphates such as tricresylphosphate in installations comprising industrial turbines on the ground such as offshore platforms.
- prophylaxis of the aerotoxic syndrome is meant the decrease in the occurrence and / or the intensity, or even the virtual disappearance or the total disappearance, of at least one symptom identified as being linked to an acute or chronic exposure. individuals to aircraft cabin air contaminated with oils such as turbine oils or hydraulic oils in the form of gas and / or aerosols.
- prophylaxis of aerotoxic syndrome refers to the decrease in occurrence, or even virtual disappearance or complete disappearance
- RECTIFIED SHEET (RULE 91) ISA / EP multiple symptoms, preferably all symptoms, identified as being related to acute or chronic exposure of individuals to aircraft cabin air contaminated with oils such as turbine oils or hydraulic oils in the form of gases, products dispersed in the air, aerosol types.
- the symptom may be a neurological, neurobehavioural, neuromotor and / or reproductive symptom.
- the symptoms whose occurrence and / or intensity can be reduced by the use according to the invention, there may be mentioned, for example, psychological or psychosomatic disorders, chronic fatigue syndrome, severe migraines, multiple chemical sensitivity. , mysterious viral infections, sleep disturbances, depression, stress and anxiety.
- smoke event denotes the acute or chronic, preferably acute, exposure of at least one individual to aircraft cabin air contaminated with oils such as turbine oils or hydraulic oils. in the form of gas and / or aerosol.
- oils such as turbine oils or hydraulic oils. in the form of gas and / or aerosol.
- a smoke event if significant, can be detected in particular by the perception of a characteristic unpleasant odor, typical of "dirty socks” or "wet dog". In the most severe cases, for example following the breakage of a bearing in the turbine, smoke or a thick white mist may be visible.
- the present invention can thus relate to a method of lubricating a machine / device, such as aircraft or air-derivative turbines, comprising the following steps:
- non-neurotoxic or very low toxicity oil (risk level at a score of 0), preferably free of tricresyl phosphate and / or its analogues, said oil comprising at least one antiwear agent selected from a compound polyphosphorus of formula (I) wherein each of R1, R2, R3 and R4 is independently selected from: an alkyl group, an O-alkyl group, an aryl group, an or O-aryl group,
- A is a divalent group selected from a linear alkylene group comprising from 7 to 36 carbon atoms or branched from 6 to 36 carbon atoms, a monocyclic, polycyclic or polyaromatic arylene group or an aralkylene group, each of Xi and X ⁇ is independently a single bond, an oxygen atom or a nitrogen atom, and n is an integer between 1 and 5,
- Example 1 Toxicity study and in particular neurotoxicity study
- the polyphosphorus compounds according to the invention were studied and compared with other phosphorus compounds, in particular with TCP, in terms of cholinesterase inhibition, 3D molecular modeling by spherical harmonics, and in terms of QSAR modeling for neurotoxicity and for reprotoxicity.
- the correlation of the results obtained made it possible to determine a "level of safety" for the use of these compounds as an anti-wear agent in oils for aircraft turbines or aero-derivatives.
- Acetylthiocholine iodide and butyrylthiocholine, and 5,5-dithiobis (2-nitrobenzoic) acid (DTNB) were purchased from Sigma Aldrich (Steinheim, Germany).
- Lyophilized BuChE from equine serum (eqBuChE, Sigma Aldrich) was dissolved in 0.1M phosphate buffer (pH 7.4) to obtain enzyme stock solutions with an enzymatic activity of 2.5 units / mL .
- Human erythrocyte AChE (hAChE, aqueous buffer solution,> 500 units / mg protein (BCA), Sigma Aldrich) was diluted in 20 mM HEPES buffer at pH 8 with 0.1% Triton X- 100 to obtain an enzyme solution with an enzyme activity of 0.25 units / mL.
- RECTIFIED SHEET (RULE 91) ISA / EP using a microplate reader (Synergy 2, Biotek, Colmar, France).
- the compounds to be tested were dissolved to 5x10 3 M in analytical grade DMSO. Donepezil or tacrine were used as reference standards. The rate of increase in absorption at 412 nm was determined 4 minutes after the addition of the acetyl or butyrylthiocholine iodide solution. The tests were carried out with a blank containing all the compounds except acetyl or butyrylthiocholine, in order to take account of non-enzymatic reactions.
- Clusters 1 and 2 Two clusters (clusters 1 and 2) were defined by similarity from in particular monophosphate compounds known to be neurotoxic and reprotoxic such as ir ⁇ (ortho-cresyl) phosphate ToCP, tri (mefa-cresyl) phosphate, tri (para- cresyl) phosphate, trixylylphosphate and cresyl phosphate of saligenin.
- monophosphate compounds known to be neurotoxic and reprotoxic such as ir ⁇ (ortho-cresyl) phosphate ToCP, tri (mefa-cresyl) phosphate, tri (para- cresyl) phosphate, trixylylphosphate and cresyl phosphate of saligenin.
- cluster 5 A third cluster of probably toxic compounds has been identified (cluster 5), including in particular a CMR reprotoxic mutagenic mutagenic compound such as tri (n-butylphosphate).
- the degrees of neurotoxicity and reprotoxicity of the various compounds used according to the invention and of other monophosphate compounds were evaluated by QSAR (quantitative structure-activity relationship) modeling.
- the training set was defined with chemical structures compiled from several publicly available sources: HSBD (Hazardous Substances Data Bank), EPA (U. S. Environmental Protection Agency), ECHA (European Chemicals Agency) and NTP (National
- the validation set was constructed using compounds from different datasets than those used for the practice set. The molecules already present in the training set have been removed.
- the validation set consisted of 70 compounds classified as neurotoxic compounds, 506 compounds classified as reprotoxic and 256 compounds classified as neither neurotoxic nor reprotoxic and forming the non-toxic validation set.
- a generalized linear model (GLM) method was chosen to perform a quantitative structure / activity relationship (QSAR) approach.
- GLM models were trained separately to discriminate the chemical structures (i) between neurotoxic and non-neurotoxic compounds and (ii) between reprotoxic and non-reprotoxic compounds. This approach resulted in a GLM model with 210 meaningful descriptors within training games.
- the performance of the QSAR models was measured by Receiver Operator Characteristic (ROC) curves and resulted in area under the curve (AUC) values of 0.90 and above for the prediction of neurotoxicity. and reprotoxicity, respectively.
- ROC Receiver Operator Characteristic
- the QSAR models were then used to predict (i) the categories of neurotoxicity of the compounds in the validation set (i.e. the neurotoxic / non-neurotoxic categorization), (ii) the categories of reprotoxicity of compounds in the validation set (i.e. reprotoxic / non-reprotoxic categorization).
- the performance of the QSAR models was measured by area under the curve (AUC) values and provided significant values of 0.70 and greater for the prediction of neurotoxicity and reprotoxicity, respectively.
- AUC area under the curve
- GLM-based QSAR models were then used to study the polyphosphorus compounds according to the invention.
- reagent A dialcohol, diamine, or aminoalcohol
- reagent A dialcohol, diamine, or aminoalcohol
- the reaction medium is diluted with toluene, approximately 10 volumes relative to reagent A.
- the reaction medium is heated between 25-110 ° C then using the dropping funnel, 2.2 molar equivalents of phosphate chloride are introduced dropwise.
- the triethylamine salt formed is removed by filtration and then washed with 5 volumes of ethyl acetate.
- the filtrate is then washed twice with 0.1 N HCl solution, twice with 0.1 N KOH solution and then with water until neutral pH.
- the organic phase is then dried with MgSQ4, filtered and then concentrated under reduced pressure.
- ISA / EP obtained is purified either by chromatography on silica gel, or by liquid-liquid extraction, or by precipitation.
- the products thus obtained are characterized by GC (gas chromatography) or GPC (gel permeation chromatography) chromatography, by 1 H and / or 31 P NMR analyzes. The yields obtained vary between 15 and 75%.
- the results of the tests carried out are shown in Fig. 2. to 9.
- the penultimate column corresponds to a risk level score with respect to the safety of these molecules which can be used in oils such as turbine oils and their alleged toxicity in the cabin.
- a score of 5 corresponds to a very high risk in terms of neurotoxicity and / or reprotoxicity, while scores of 0 or 1 correspond to a very low or no level of risk.
- the level of risk is determined by the sum of the factors corresponding to each of the risks assessed independently based on the in vitro experimental results of inhibition (IC 50 hAChE and IC 50 eqBuChE), semi-empirical prediction (QSAR neurotoxicity and QSAR reprotoxicity models ), and molecular modeling via spherical harmonics (cluster classification) and it can range from 0 to 5.
- a value of 0 indicates no risk, and a value of 5 indicates a very high multiple risk.
- a factor of 0 or 1 is assigned depending on whether the value is above or below a threshold. The following thresholds are applied: 15 mg / L for ICso for hAChE, 15 mg / L for ICso for eqBuChE, 0.2% for neurotoxicity, 3% for reprotoxicity.
- Tricresylphosphate (CAS 1330-78-5) corresponds to the commercial product Durad 125 (https://echa.europa.eu/fr/substance-information/-/substanceinfo/100.239.100)
- Compound E Trixylylphosphate (CAS 25155-23-1) (https://echa.europa.eu/fr/registration-
- Compound M tri (n-butylphosphate) (CAS 126-73-8) https://echa.europa.eu/en/registration- dossier / - / registered-dossier / 13548
- Compound N tris (chloroethyl) phosphate (CAS 115-96-8) https://echa.europa.eu/en/substance- information / - / substanceinfo / 100.003.744
- the compounds of the triarylphosphates type (TCP family) entirely belong to cluster 1 presenting a level of risk varying from 2 to 5 with an average of 3.6 out of the 8 molecules presenting complete characteristics.
- the compounds of cluster 1 appear, according to the 3D modeling approach of spherical harmonics, in the form of a "three-bladed helix" on the basis of two perpendicular planes at the level of the center or the heart of the molecule while the compounds of cluster 3 have a rather deployed and flattened shape resembling a butterfly shape.
- the molecules resulting from the modeling work by spherical harmonics are represented in FIG. 1. These compounds are therefore non-neurotoxic and non-reprotoxic alternatives to tricresyl phosphate and its tri-arylphosphates analogues.
- compound I2 described in patent application WO2010 / 149690, exhibits reduced inhibition on butyrylcholinesterase, but is found to be active with respect to acetylcholinesterase. Modeling classifies the latter as part of cluster 1, which confirms the experimental result on acetylcholinesterase.
- this sub-assembly is suitable for / configured for the prophylaxis of aerotoxic syndrome in particular in the event of a smoke event.
- This sub-assembly by virtue of its characteristics, makes it possible to form a turbine oil, for example for aviation, which is suitable for and / or configured to make it possible to increase the level of safety in aviation and in other aero-derivative applications.
- the other polyphosphorus compounds and in particular the other polyphosphorus compounds used as anti-wear agent in an oil and known from the prior art do not exhibit this new technical effect (ie: reduce and / or prevent neurotoxicity of an oil or for the prophylaxis of aerotoxic syndrome).
- the other compounds do not exhibit this new technical effect (ie: reduce and / or prevent neurotoxicity of an oil or for the prophylaxis of aerotoxic syndrome).
- the other compounds do not exhibit this new technical effect (ie: reduce and / or prevent neurotoxicity of an oil or for the prophylaxis of aerotoxic syndrome).
- ISA / EP anti-wear and other organophosphorus compounds known and used in the field of lubricants and aircraft oils T are neurotoxic (such as compounds E, P, 11-3, L, R and M, the latter being used in hydraulic fluids of the 'aviation).
- compound 13 does not show signs of toxicity to human health.
- the table in FIG. 5 shows that this compound 13 is a mixture of neurotoxic compounds belonging to cluster 1 including triphenylphosphate and tri (p-tertbutylphenyl) phosphate.
- compound A which according to the ECHA website does not show any sign of neurotoxicity, and yet presents a risk level 4.
- a person skilled in the art would therefore not have been encouraged or encouraged. in selecting the subset formed by the compounds of general formula (I) (in particular from known and public generic toxicity data) in order to reduce and / or prevent the neurotoxicity of an oil or for the prophylaxis of aerotoxic syndrome.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Lubricants (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2005253A FR3110593B1 (fr) | 2020-05-20 | 2020-05-20 | Utilisation d’huiles comprenant des additifs anti-usure non neurotoxiques |
US16/878,857 US11230683B2 (en) | 2020-05-20 | 2020-05-20 | Use of oils comprising non-neurotoxic anti-wear additives |
PCT/EP2021/063200 WO2021233946A1 (fr) | 2020-05-20 | 2021-05-18 | Utilisation d'huiles comprenant des additifs anti-usure non neurotoxiques |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3938478A1 true EP3938478A1 (fr) | 2022-01-19 |
EP3938478B1 EP3938478B1 (fr) | 2023-01-18 |
Family
ID=75904962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21725231.1A Active EP3938478B1 (fr) | 2020-05-20 | 2021-05-18 | Utilisation d'huiles comprenant des additifs anti-usure non neurotoxiques |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230242830A1 (fr) |
EP (1) | EP3938478B1 (fr) |
JP (1) | JP2023525929A (fr) |
CN (1) | CN115916929B (fr) |
AU (1) | AU2021277484A1 (fr) |
BR (1) | BR112022023447A2 (fr) |
CA (1) | CA3179169A1 (fr) |
WO (1) | WO2021233946A1 (fr) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0612837A1 (fr) * | 1993-01-06 | 1994-08-31 | Akzo Nobel N.V. | Lubrifiant, polyphénylène éther, contenant un composé bis(dihydrocarbylphosphate) hydrocarbyl |
US5560849A (en) | 1994-12-23 | 1996-10-01 | Fmc Corporation | Synthetic ester lubricant having improved antiwear properties |
JP2001306530A (ja) | 2000-04-25 | 2001-11-02 | Canon Inc | ネットワークシステム、リモートアクセス実行装置、方法、及びコンピュータ読み取り可能な記憶媒体 |
US20080182770A1 (en) * | 2007-01-26 | 2008-07-31 | The Lubrizol Corporation | Antiwear Agent and Lubricating Compositions Thereof |
FR2924122B1 (fr) | 2007-11-28 | 2009-12-25 | Nyco Sa | Agent anti-oxydant et/ou anti-corrosion, composition lubrifiante contenant ledit agent et procede pour preparer celui-ci |
JP5395453B2 (ja) * | 2009-02-16 | 2014-01-22 | Jx日鉱日石エネルギー株式会社 | 無段変速機油組成物 |
FR2946983B1 (fr) | 2009-06-23 | 2011-12-23 | Nyco | Agents anti-usure a neurotoxicite reduite |
CN102834493B (zh) | 2010-03-26 | 2015-05-27 | 株式会社Adeka | 润滑油添加剂及含有其的润滑油组合物 |
US8623795B2 (en) * | 2010-07-27 | 2014-01-07 | Exxonmobil Research And Engineering Company | Method for maintaining antiwear performance of turbine oils containing polymerized amine antioxidants and for improving the deposit formation resistance performance of turbine oils containing monomeric and/or polymeric antioxidants |
EP2598489B1 (fr) | 2010-07-27 | 2018-11-07 | ExxonMobil Research and Engineering Company | Utilisation de bis-phosphates de diphényle pour améliorer la résistance contre la formation de dépôts d'huiles de turbine contenant des antioxydants aminés |
DE102013003282B4 (de) | 2013-02-27 | 2016-09-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Trikresylphosphat-freies Öl und dessen Verwendung |
US9200230B2 (en) * | 2013-03-01 | 2015-12-01 | VORA Inc. | Lubricating compositions and methods of use thereof |
WO2015026566A1 (fr) * | 2013-08-20 | 2015-02-26 | Icl-Ip America Inc. | Lubrifiant ayant des propriétés anti-usure améliorées |
-
2021
- 2021-05-18 AU AU2021277484A patent/AU2021277484A1/en active Pending
- 2021-05-18 BR BR112022023447A patent/BR112022023447A2/pt unknown
- 2021-05-18 EP EP21725231.1A patent/EP3938478B1/fr active Active
- 2021-05-18 WO PCT/EP2021/063200 patent/WO2021233946A1/fr unknown
- 2021-05-18 JP JP2022571173A patent/JP2023525929A/ja active Pending
- 2021-05-18 US US17/926,287 patent/US20230242830A1/en active Pending
- 2021-05-18 CA CA3179169A patent/CA3179169A1/fr active Pending
- 2021-05-18 CN CN202180044132.2A patent/CN115916929B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
US20230242830A1 (en) | 2023-08-03 |
CN115916929A (zh) | 2023-04-04 |
EP3938478B1 (fr) | 2023-01-18 |
BR112022023447A2 (pt) | 2022-12-20 |
CN115916929B (zh) | 2024-01-30 |
AU2021277484A1 (en) | 2023-01-05 |
WO2021233946A1 (fr) | 2021-11-25 |
JP2023525929A (ja) | 2023-06-19 |
CA3179169A1 (fr) | 2021-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abou-Donia et al. | Sarin (GB, O-isopropyl methylphosphonofluoridate) neurotoxicity: critical review | |
Montanari et al. | Fatty acid amide hydrolase (FAAH), acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE): networked targets for the development of carbamates as potential anti-Alzheimer’s disease agents | |
Mangas et al. | Neurotoxic effects associated with current uses of organophosphorus compounds | |
Facanha et al. | Evaluation of antioxidant properties of a phosphorated cardanol compound on mineral oils (NH10 and NH20) | |
Bernal et al. | Structure− activity relationships of cinnamate ester analogues as potent antiprotozoal agents | |
EP2446005B1 (fr) | Agents antiusure présentant une neurotoxicité réduite | |
DE69726449T2 (de) | Aminophosphonsäure-derivate als arzneimittel | |
WO2014142549A1 (fr) | Composé carbamate de phényle et composition pour prévenir ou traiter une maladie associée à une perte de mémoire le comprenant | |
EP3938478B1 (fr) | Utilisation d'huiles comprenant des additifs anti-usure non neurotoxiques | |
EP4114910B1 (fr) | Composés organophosphorés spécifiques comme agents antiusure non neurotoxiques | |
FR3110593A1 (fr) | Utilisation d’huiles comprenant des additifs anti-usure non neurotoxiques | |
Sobotka et al. | Choleic acids: The separation of optical antipodes by means of co-ordination compounds1 | |
US20140090292A1 (en) | Bisphenol a compounds as markers for liquid hydrocarbons and other fuels and oils | |
Bashir et al. | Urease inhibition potential and molecular docking of dihydroquercetin and dihydromyricetin isolated from Picea smithiana (wall) Boiss. | |
Schopfer et al. | Reaction kinetics of biotinylated organophosphorus toxicant, FP-biotin, with human acetylcholinesterase and human butyrylcholinesterase | |
Johnson | The mechanism of delayed neuropathy caused by some organophosphorus esters: using the understanding to improve safety | |
US11230683B2 (en) | Use of oils comprising non-neurotoxic anti-wear additives | |
Tuin et al. | Activity-based protein profiling reveals broad reactivity of the nerve agent sarin | |
EP2151499A2 (fr) | Procédés pour la préparation de phosphatides | |
de Sousa Rios et al. | Cashew nut shell liquid: a versatile raw material utilized for syntheses of phosphorus compounds | |
FR2791981A1 (fr) | Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications | |
JPH06228170A (ja) | ホスファチジルクロマノール誘導体、その製造方法、抗酸化剤及び乳化剤 | |
PT105914A (pt) | Utilização de um extracto de bagaço de azeitona inibidor da enzima acetilcolinesterase no tratamento de perturbações colinérgicas | |
Reji Thomas | Design and Synthesis of Peripherally Selective Endocannabinoid Enzyme Inhibitors for Ocular Indications | |
WO2023209038A1 (fr) | Utilisation d'un antioxydant pour réduire et/ou prévenir la toxicité d'une composition lubrifiante |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210809 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20220624 |
|
INTG | Intention to grant announced |
Effective date: 20220708 |
|
INTG | Intention to grant announced |
Effective date: 20220708 |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20220824 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602021001275 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1544699 Country of ref document: AT Kind code of ref document: T Effective date: 20230215 Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20230118 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1544699 Country of ref document: AT Kind code of ref document: T Effective date: 20230118 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230516 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230518 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230418 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230313 Year of fee payment: 3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230518 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230419 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602021001275 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 |
|
26N | No opposition filed |
Effective date: 20231019 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230518 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230118 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20240214 Year of fee payment: 4 Ref country code: FR Payment date: 20240209 Year of fee payment: 4 |